CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 23 enrolled
Drug / intervention
Carboplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01706939
NCT01706939Phase 3Active
CompareCT.gov

The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer

Icahn School of Medicine at Mount Sinai·interventional·Posted Oct 15, 2012·Updated Apr 9, 2026

In Brief

A Phase 3 clinical trial evaluating Reduced Dose Radiation, Standard Dose Radiation, and 1 other intervention for Squamous Cell Carcinomas. Active but no longer recruiting, targeting 23 participants across 1 site.

Detailed Summary

This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinomas
CountriesUnited States
CollaboratorsBiodesign Institute, Arizona State University

Timeline

Phase 3Active
20132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035
First PostedOct 15, 2012
Enrollment StartSep 1, 2012
Primary CompletionApr 1, 2020
Study CompletionMay 1, 2035
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 13.7 years ago

Interventions

Reduced Dose Radiationradiation

Reduced Dose Radiation (5600 cGy) dose radiotherapy

Standard Dose Radiationradiation

Standard Dose Radiation (7000 cGy) dose radiotherapy

Carboplatindrug

Day 1, every 7 days ( + 2 days)